News

Odanacatib, which is firm’s investigational once-weekly cathepsin K inhibitor, has reached the primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with

According to Hungarian news agency MTI, the company’s research and development division has produced a drug comprising deuterium-depleted water or DDW, which has potential to trim down the

The AZD3293 is an oral beta secretase cleaving enzyme (BACE) inhibitor, which significantly reduced amyloid beta levels in the cerebro-spinal fluid of Alzheimer’s patients and healthy volunteers in

America will also set up additional field hospitals, deliver more health-care personnel and training health workers in Liberia, Sierra Leone and Guinea, which are among the nations that

With aim to finance the transaction through a combination of cash on hand and debt, Cognizant has already secured $1bn of committed financing in support of the transaction,

GSK paid $1.5m to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target discovered by Five Prime using its proprietary library

The first of these agreements is a joint development program with St. Jude Children’s Research Hospital (Memphis, Tennessee, United States, "St. Jude") and the non-profit public-private partnership Medicines

The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer (CRPC) who have rising Prostate-Specific Antigen (PSA) levels and no detectable metastases. The trial is designed

Results from the study, presented during the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), also confirmed the safety profile of the combination